Micronized purified flavonoid fraction (MPFF) is a widely prescribed and extensively investigated venoactive drug (VAD). The standard dosage for MPFF is 500 mg administered twice daily. However, a new daily dose of 1000 mg has just been introduced.
Objective:
This study investigated whether a daily dose of 1000 mg MPFF could be implemented and embraced by the public and still has the same therapeutic effects as conventional pharmaceuticals.
Methods:
For this meta-analysis, we searched MEDLINE, Embase, Science of Web, Cochrane, and PubMed databases and forward and backward citations for studies published between database inception and March 2023. Three randomized controlled trials (RCTs) of comparison of different dosages of MPFF to evaluate whether there is a significant difference between them were included, without language or date restrictions. Due to the small sample size of the study included, we conducted a simple sensitivity test using a one-by-one exclusion method, and the results showed that the study did not affect the final consolidation conclusion. The quality of the evidence was assessed using the Cochrane risk-of-bias tool.
Results:
Out of 232 studies, 99 were eligible and 39 RCTs had data, all with low to moderate bias. Overall, 1924 patients (experimental group: 967, control group: 957) in 3 RCTs met the criteria. There is no significant difference in patient compliance, efficacy, clinical adverse events, and quality of life scores between MPFF 1000 mg once daily and MPFF 500 mg twice daily (standardized mean difference [SMD]: 0.049 [0.048, 0.145], p=0.321, risk ratio [RR]: 0.981 [0.855, 1.125], p=0.904, and SMD: 0.063 [0.034, 0.160], p=0.203).
Interpretation:
In symptomatic chronic venous disease patients, MPFF 1000 mg once daily and MPFF 500 mg twice daily improve patient compliance, lower limb discomfort, clinical adverse events, and quality of life scores similarly. Regular medical care should recommend MPFF 1000 mg daily more often.
Clinical Impact
Micronized purified flavonoid fraction (MPFF) is a popular venoactive medication (VAD) in modern medicine.
MPFF is effective in treating lower extremity venous problems.
Currently, besides conventional 500 mg tablets, there exist alternative dosage forms such as solutions, chewable tablets, and other novel formulations for MPFF.
The excessive frequency and amount of medication may have a negative impact on patient adherence.
ProchaskaJHArnoldNFalckeA, et alChronic venous insufficiency, cardiovascular disease, and mortality: a population study. Eur Heart J. 2021;42:4157–4165. doi:10.1093/eurheartj/ehab495.
2.
VuylstekeMEColmanRThomisS, et alAn epidemiological survey of venous disease among general practitioner attendees in different geographical regions on the globe: the final results of the vein consult program. Angiology. 2018;69(9):779–785. doi:10.1177/0003319718759834.
3.
Beebe-DimmerJLPfeiferJREngleJS, et alThe epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005;15(3):175–184. doi:10.1016/j.annepidem.2004.05.015.
4.
YangQZhaoYChenX, et alAssociation between vein diameters, reflux characteristics, and clinical severity in patients with chronic venous insufficiency in Northwest China. J Vasc Surg Venous Lymphat Disord. 2021;9(2):401–408. doi:10.1016/j.jvsv.2020.07.006.
5.
KatsenisK.Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol. 2005;3(1):1–9. doi:10.2174/1570161052773870.
6.
MansilhaASousaJ.Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19:1669. doi:10.3390/ijms19061669.
7.
GodebergePSheikhPLohsiriwatV, et alMicronized purified flavonoid fraction in the treatment of hemorrhoidal disease. J Comp Effect Res. 2021;10:801–813. doi:10.2217/cer-2021-0038.
8.
ZagriadskiĭEABogomazovAMGolovkoEB.Conservative treatment of hemorrhoids: results of an observational multicenter study. Adv Ther. 2018;35:1979–1992. doi:10.1007/s12325-018-0794-x.
9.
NicolaidesAN.The benefits of micronized purified flavonoid fraction (MPFF) throughout the progression of chronic venous disease. Adv Ther. 2020;37(suppl 1):1–5. doi:10.1007/s12325-019-01218-8.
10.
KakkosSKNicolaidesAN.Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143–154. doi:10.23736/S0392-9590.18.03975-5.
11.
De MaeseneerMGKakkosSKAherneT, et alEditor’s choice—European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. doi:10.1016/j.ejvs.2021.12.024.
12.
GavrilovSGKaralkinAVMoskalenkoYP, et alEfficacy of two micronized purified flavonoid fraction dosing regimens in the pelvic venous pain relief. Int Angiol. 2021;40(3):180–186. doi:10.23736/S0392-9590.21.04579-X.
13.
GavrilovSGMoskalenkoYPKaralkinAV.Effectiveness and safety of micronized purified flavonoid fraction for the treatment of concomitant varicose veins of the pelvis and lower extremities. Curr Med Res Opin. 2019;35(6):1019–1026. doi:10.1080/03007995.2018.1552043.
14.
GavrilovSGTurischevaOO.Conservative treatment of pelvic congestion syndrome: indications and opportunities. Curr Med Res Opin. 2017;33(6):1099–1103. doi:10.1080/03007995.2017.1302414.
15.
FalagasMEKaragiannisAKNakoutiT, et alCompliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials. PLoS ONE. 2015;10:e116207. doi:10.1371/journal.pone.0116207.
16.
KardasP.Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother. 2007;59(3):531–536. doi:10.1093/jac/dkl528.
17.
LeenenFHWilsonTWBolliP, et alPatterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13(10):914–920.
18.
MansilhaACaldevillaHPuskásA, et al. MPFF 1000 mg chewable once daily vs. MPFF 500 mg twice daily in chronic venous disease: the double-blind, randomized, non-inferiority CHEWY trial. Int Angiol. 2022;41(6):464–475. doi:10.23736/S0392-9590.22.04987-2.
19.
PageMJMcKenzieJEBossuytPM, et alThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ-Brit Med J. 2021:372; n71. doi:10.1136/bmj.n71.
20.
HigginsJPThompsonSGDeeksJJ, et alMeasuring inconsistency in meta-analyses. BMJ-Brit Med J. 2003;327:557–560. doi:10.1136/bmj.327.7414.557.
21.
CarpentierPKaretovaDGutierrezLR, et alClinical efficacy of a new once-daily 1000 mg oral suspension of micronized purified flavonoid fraction in patients suffering from symptomatic chronic venous disease. Phlebology. 2018;33:719–720. doi:10.1177/0268355518804455.
22.
KirienkoARadakD.Clinical acceptability study of once-daily versus twice-daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial. Int Angiol. 2016;35(4):399–405.
23.
CatarinellaFSNiemanFHWittensCH.An overview of the most commonly used venous quality of life and clinical outcome measurements. J Vasc Surg Venous Lymphat Disord. 2015;3:333–340. doi:10.1016/j.jvsv.2014.09.003.
24.
LurieFPassmanMMeisnerM, et alThe 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–352. doi:10.1016/j.jvsv.2019.12.075.
25.
Lyseng-WilliamsonKAPerryCM.Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs. 2003;63(1):71–100. doi:10.2165/00003495-200363010-00005.
26.
AntignaniPLLazarashviliZMonederoJL, et alDiagnosis and treatment of pelvic congestion syndrome: UIP consensus document. Int Angiol. 2019;38(4):265–283. doi:10.23736/S0392-9590.19.04237-8.
27.
ClarkMRTaylorAC.Pelvic venous disorders: an update in terminology, diagnosis, and treatment. Semin Intervent Radiol. 2023;40(4):362–371. doi:10.1055/s-0043-1771041.
28.
SimsekMBurakFTaskinO.Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial. Clin Exp Obstet Gynecol. 2007;34(2):96–98.
29.
AkhmetzianovRVBredikhinRA.Clinical efficacy of conservative treatment with micronized purified flavonoid fraction in female patients with pelvic congestion syndrome. Pain Ther. 2021;10(2):1567–1578. doi:10.1007/s40122-021-00312-6.
30.
GergesSHWahdanSAElsherbinyDA, et alPharmacology of diosmin, a citrus flavone glycoside: an updated review. Eur J Drug Metab Pharmacokinet. 2022;47(1):1–18. doi:10.1007/s13318-021-00731-y.
31.
StruckmannJRNicolaides ANFlavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology. 1994;45(6):419–428. doi:10.1177/000331979404500602.
32.
ZhengYZhangRShiW, et alMetabolism and pharmacological activities of the natural health-benefiting compound diosmin. Food Funct. 2020;11:8472–8492. doi:10.1039/d0fo01598a.
33.
FeldoMWójciak-KosiorMSowaI, et alEffect of diosmin administration in patients with chronic venous disorders on selected factors affecting angiogenesis. Molecules. 2019;24:3316. doi:10.3390/molecules24183316.
34.
GopalakrishnanVIyyam PillaiSSubramanianSP.Synthesis, spectral characterization, and biochemical evaluation of antidiabetic properties of a new zinc-diosmin complex studied in high fat diet fed-low dose streptozotocin induced experimental type 2 diabetes in rats. Biochem Res Int. 2015;2015:350829. doi:10.1155/2015/350829.
35.
SöylemezHKiliçSAtarM, et alEffects of micronised purified flavonoid fraction on pain, semen analysis and scrotal color Doppler parameters in patients with painful varicocele; results of a randomized placebo-controlled study. Int Urol Nephrol. 2012;44(2):401–408. doi:10.1007/s11255-011-0038-3.
36.
RabeEAgusGBRoztocilK.Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428–436.
37.
MaggioliACarpentierP.Efficacy of MPFF 1000 mg oral suspension on CVD C0s-C1-related symptoms and quality of life. Int Angiol. 2019;38(2):83–89. doi:10.23736/S0392-9590.18.04054-3.
38.
NicolaidesAKakkosSBaekgaardN, et alManagement of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37:181–254. doi:10.23736/S0392-9590.18.03999-8.
UlloaJH.Micronized purified flavonoid fraction (MPFF) for patients suffering from chronic venous disease: a review of new evidence. Adv Ther. 2019;36(suppl 1):20–25. doi:10.1007/s12325-019-0884-4.
41.
MansilhaA.Early stages of chronic venous disease: medical treatment alone or in addition to endovenous treatments. Adv Ther. 2020;37(suppl 1):13–18. doi:10.1007/s12325-019-01217-9.
42.
ClaxtonAJCramerJPierceC.A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310. doi:10.1016/s0149-2918(01)80109-0.
43.
YeawJBennerJSWaltJG, et alComparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740. doi:10.18553/jmcp.2009.15.9.728.
44.
LalibertéFBookhartBKNelsonWW, et alImpact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013;6(3):213–224. doi:10.1007/s40271-013-0020-5.
45.
LauffenburgerJCHaffNMcDonnellME, et alExploring patient experiences coping with using multiple medications: a qualitative interview study. BMJ Open. 2021;11:e46860. doi:10.1136/bmjopen-2020-046860.
46.
BaryakovaTHPogostinBHLangerR, et alOvercoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387–409. doi:10.1038/s41573-023-00670-0.
47.
ChudekJKocełakPZiajaD, et alCompliance in pharmacotherapy in patients with chronic venous disorders. Int Angiol. 2012;31(4):393–401.
